Discovery of schizophrenia drug targets from DISC1 mechanisms

Published on March 28, 2013   20 min

Other Talks in the Series: Small Molecule Drug Discovery

Other Talks in the Series: Drug Discovery and Development in the Neurosciences

I'm Atsushi Kamiya, Assistant Professor, Department of Psychiatry, Johns Hopkins University. Today, I will talk about "The Discovery of Schizophrenia Drug Targets from DISC1 Mechanisms."
The history of modern pharmacological treatment of major mental disorders, including schizophrenia, started as a serendipitous identification of antipsychotic effects of chlorpromazine in 1952. Most neuroleptics that are currently being used in clinical psychiatry have been developed based on the findings that chlorpromazine exerts its effect by blocking the dopamine receptors, but not based on etiological rationale. In the past decade or so, psychiatric genetics have finally identified separate genetic risk factors for schizophrenia. This encouraged us to develop our research utilizing modern neuroscience approaches with the goal of finding another therapeutic target via understanding risk genes associated with molecular pathways.
In this regard, DISC1 is one of the promising risk gene for major mental conditions. Today, I will first talk about how DISC1 is identified as a risk gene for major mental disorders. Then I will discuss potential therapeutic strategies based on the structure and the motif of DISC1 protein. Next, I will present several DISC1-associated pathways as potential drug targets. Finally, I'll discuss the molecular complexities of DISC1 and propose how we could address this matter. Let's start with the discovery of the disrupted in

Discovery of schizophrenia drug targets from DISC1 mechanisms

Embed in course/own notes